Genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in multiple myeloma reveals the importance of Polycomb gene targeting and highlights EZH2 as a potential therapeutic target
Autor: | Kenneth Nilsson, Stefan Enroth, Peter Brown, Anders Österborg, Jian Jin, Fredrik Öberg, Johanna Ungerstedt, Anqi Ma, Mohammad Alzrigat, Prasoon Agarwal, Alba Atienza Párraga, Umashankar Singh, Antonia Kalushkova, Helena Jernberg-Wiklund |
---|---|
Jazyk: | angličtina |
Rok vydání: | 2016 |
Předmět: |
0301 basic medicine
Oncology medicine.medical_specialty medicine.medical_treatment H3K27me3 Down-Regulation Polycomb-Group Proteins macromolecular substances UNC1999 Methylation Targeted therapy Histones 03 medical and health sciences Histone H3 0302 clinical medicine Internal medicine medicine Humans Enhancer of Zeste Homolog 2 Protein EZH2 Molecular Targeted Therapy Enzyme Inhibitors Multiple myeloma Hematology biology business.industry Gene Expression Profiling Lysine Epigenome medicine.disease Chromatin 3. Good health Gene expression profiling multiple myeloma Polycomb 030104 developmental biology 030220 oncology & carcinogenesis Immunology biology.protein business PRC2 Research Paper |
Zdroj: | Oncotarget |
ISSN: | 1949-2553 |
Popis: | // Prasoon Agarwal 1, * , Mohammad Alzrigat 1, * , Alba Atienza Parraga 1 , Stefan Enroth 1 , Umashankar Singh 2 , Johanna Ungerstedt 3 , Anders Osterborg 4 , Peter J. Brown 5 , Anqi Ma 6 , Jian Jin 6 , Kenneth Nilsson 1 , Fredrik Oberg 1 , Antonia Kalushkova 1, ‡ , Helena Jernberg-Wiklund 1, ‡ 1 Science for Life Laboratory, Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University, Uppsala, Sweden 2 Department of Biological Engineering, Indian Institute of Technology, Gandhinagar, Gujarat, India 3 Department of Medicine, Center for Hematology and Regenerative Medicine (HERM), Karolinska Institute Huddinge, Stockholm, Sweden 4 Department of Oncology-Pathology, Karolinska University Hospital Solna, Stockholm, Sweden 5 Structural Genomics Consortium, University of Toronto, Toronto, Ontario, Canada 6 Departments of Structural and Chemical Biology, Oncological Sciences, and Pharmacology and Systems Therapeutics, Icahn School of Medicine at Mount Sinai, New York, NY, USA * These authors have contributed equally to this work ‡ Corresponding last co-authors Correspondence to: Helena Jernberg-Wiklund, e-mail: helena.jernberg_wiklund@igp.uu.se Antonia Kalushkova, e-mail: antonia.kalushkova@igp.uu.se Keywords: multiple myeloma, Polycomb, EZH2, H3K27me3, UNC1999 Received: June 03, 2015 Accepted: December 29, 2015 Published: January 7, 2016 ABSTRACT Multiple myeloma (MM) is a malignancy of the antibody-producing plasma cells. MM is a highly heterogeneous disease, which has hampered the identification of a common underlying mechanism for disease establishment as well as the development of targeted therapy. Here we present the first genome-wide profiling of histone H3 lysine 27 and lysine 4 trimethylation in MM patient samples, defining a common set of active H3K4me3-enriched genes and silent genes marked by H3K27me3 (H3K27me3 alone or bivalent) unique to primary MM cells, when compared to normal bone marrow plasma cells. Using this epigenome profile, we found increased silencing of H3K27me3 targets in MM patients at advanced stages of the disease, and the expression pattern of H3K27me3-marked genes correlated with poor patient survival. We also demonstrated that pharmacological inhibition of EZH2 had anti-myeloma effects in both MM cell lines and CD138+ MM patient cells. In addition, EZH2 inhibition decreased the global H3K27 methylation and induced apoptosis. Taken together, these data suggest an important role for the Polycomb repressive complex 2 (PRC2) in MM, and highlights the PRC2 component EZH2 as a potential therapeutic target in MM. |
Databáze: | OpenAIRE |
Externí odkaz: |